Guided Therapeutics (GTHP) Price to Earnings (2021 - 2026)

Guided Therapeutics has disclosed Price to Earnings across 6 years of filings, most recently posting 38.36 for Q2 2026.

• In Q2 2026, Price to Earnings fell 239793.08% year-over-year to 38.36; the TTM figure through Jun 2026 stood at 6.36 (down 125830.82% YoY), while the FY2025 annual figure was 5.25, down 178.77% from the prior year.
• Price to Earnings came in at 38.36 for Q2 2026 at Guided Therapeutics, down from 0.01 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 0.01 in Q2 2023 to a low of 38.36 in Q2 2026.
• Average Price to Earnings over 5 years is 4.88, with a median of 0.02 recorded in 2023.
• Year-over-year, Price to Earnings jumped 99.95% in 2023 and sank 239793.08% in 2026.
• Over 5 years, Price to Earnings stood at 5.25 in 2022, then soared by 99.7% to 0.02 in 2023, then rose by 25.59% to 0.01 in 2024, then slumped by 102.9% to 0.02 in 2025, then sank by 161043.13% to 38.36 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 38.36 in Q2 2026, 0.01 in Q1 2026, and 0.02 in Q4 2025.